T

Tessera Therapeutics

Gene Writing platform enabling precise edits

Senior Scientist - Computational Biology

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeSomerville, MA, USA

About the Job

Requirements

  • A PhD with at least 5 years of experience in an academic or industry setting, an MS with at least 10 years of experience, or a BS with at least 12 years of experience.
  • Broad knowledge of genome editing technologies and associated off-target discovery assays, including whole-genome sequencing, targeted sequencing, GUIDE-seq, Digenome-seq discovery and verification, large and small structural variations and translation effects, and next-generation sequencing quality control.
  • Hands-on experience developing, executing, and troubleshooting next-generation sequencing analysis pipelines in cloud-based environments.
  • Experience with AWS or cloud computing, version control, reproducible analysis practices, and software development best practices.
  • Experience with workflow tools such as Nextflow, Dagster, or equivalent systems.
  • Experience using artificial intelligence tools in daily work.
  • A strong computational background and significant experience in biological research.

Responsibilities

  • Work with biologists to design and run experiments.
  • Develop methods and tools for processing and interpreting molecular data.
  • Present findings to an interdisciplinary audience.
  • Design, analyze, and interpret multi-omics technologies focused on understanding gene writing systems.
  • Process, analyze, and interpret data from research and preclinical projects to develop rigorous hypotheses.
  • Collaborate with experimental scientists to ensure data is effectively utilized for high-level impact.
  • Present scientific findings to broad audiences, including senior leadership, to support decision-making in program teams.
  • Collaborate closely with Platform teams to advance technologies and deepen understanding of reagent biology.

About the Company

Tessera Therapeutics

Gene Writing platform enabling precise edits

Tessera Therapeutics focuses on genetic medicine by developing Gene Writing, a platform that makes precise and permanent changes to the human genome in cells. Its technology can perform both small and large genetic alterations, enabling targeted edits at the source of genetic diseases. The product works through a gene writing system that researchers and clinicians can apply to modify DNA sequences, with the aim of correcting disease-causing mutations. What sets Tessera apart is its emphasis on permanent, in vivo genome edits and a platform-driven approach supported by partnerships and licensing, rather than selling a single product. Revenue comes from collaborations with research institutions and pharmaceutical companies, licensing the Gene Writing technology, and potentially transferring proprietary tools to other biotech and healthcare organizations. The overarching goal is to cure genetic diseases by rewriting the genetic code, bringing about lasting therapeutic changes.

Company size
51-200
Company stage
Late Stage VC
Total funding
$682.7M
Headquarters
Somerville, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Tessera Therapeutics

See more jobs